Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Capital Expenditures (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Capital Expenditures for 17 consecutive years, with $370.0 million as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 2.12% to $370.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.3 billion through Dec 2025, up 5.05% year-over-year, with the annual reading at $1.3 billion for FY2025, 5.05% up from the prior year.
  • Capital Expenditures for Q4 2025 was $370.0 million at Bristol Myers Squibb, up from $320.0 million in the prior quarter.
  • The five-year high for Capital Expenditures was $378.0 million in Q4 2024, with the low at $173.0 million in Q1 2021.
  • Average Capital Expenditures over 5 years is $293.0 million, with a median of $281.0 million recorded in 2023.
  • The sharpest move saw Capital Expenditures soared 76.47% in 2021, then decreased 8.52% in 2022.
  • Over 5 years, Capital Expenditures stood at $320.0 million in 2021, then rose by 8.12% to $346.0 million in 2022, then dropped by 4.62% to $330.0 million in 2023, then grew by 14.55% to $378.0 million in 2024, then dropped by 2.12% to $370.0 million in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $370.0 million, $320.0 million, and $361.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.